Sitagliptin And Metformin Hydrochloride Tablet, Film Coated, Extended Release
Product Images NDC 70710-2037

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Sitagliptin And Metformin Hydrochloride (NDC 70710-2037). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (33ea875e Cb1b 4508 B538 07828d828e10 01)

Chemical structure diagram of sitagliptin, the active ingredient in Sitagliptin and Metformin Hydrochloride tablets. The structure shows rings and functional groups including trifluoromethyl and amide moieties characteristic of sitagliptin.*

FDA Label Image

Image (33ea875e Cb1b 4508 B538 07828d828e10 02)

Chemical structure of sitagliptin hydrochloride, showing its molecular arrangement with associated hydrochloride (HCl) component.*

FDA Label Image

Image (33ea875e Cb1b 4508 B538 07828d828e10 03)

A line graph showing the least squares (LS) mean change from baseline over 24 weeks in different treatment groups. The x-axis represents weeks (0 to 24), and the y-axis represents LS mean change from baseline. Six lines correspond to placebo, sitagliptin 100 mg once daily, metformin immediate-release 500 mg twice daily, metformin immediate-release 1000 mg twice daily, sitagliptin 50 mg twice daily combined with metformin immediate-release 500 mg twice daily, and sitagliptin 50 mg twice daily combined with metformin immediate-release 1000 mg twice daily.*

FDA Label Image

Image (33ea875e Cb1b 4508 B538 07828d828e10 04)

A line graph comparing the least squares mean change from baseline over 52 weeks for Sitagliptin 100 mg and Glipizide. The x-axis represents weeks from 0 to 52, and the y-axis shows the change from baseline, ranging from 0.0 to -1.5. Both lines show a decrease initially, stabilizing around weeks 24 to 36, and then slightly increasing toward week 52.*

FDA Label Image

50 mg/ 500 mg (33ea875e Cb1b 4508 B538 07828d828e10 05)

Label for Sitagliptin and Metformin Hydrochloride Extended-Release Tablets, oral use, 50 mg/500 mg strength. The package contains 60 film-coated extended-release tablets. The label includes NDC 70710-2036-6, storage instructions, child-resistant packaging notice, and manufacturer information: Zydus Lifesciences Ltd., Ahmedabad, India, and distributor Zydus Pharmaceuticals (USA) Inc., Pennington, NJ.*

FDA Label Image

50 mg/1000 mg (33ea875e Cb1b 4508 B538 07828d828e10 06)

Label for Sitagliptin and Metformin Hydrochloride Extended-Release Tablets, oral use, 50 mg/1,000 mg strength. The package contains 60 film-coated extended-release tablets. Labeled for prescription use only and distributed by Zydus Pharmaceuticals USA Inc. Additional storage and usage instructions are provided on the label.*

FDA Label Image

100 mg/1000 mg (33ea875e Cb1b 4508 B538 07828d828e10 07)

Label for Sitagliptin and Metformin Hydrochloride Extended-Release Tablets, oral use, 100 mg/1,000 mg strength. The label includes storage instructions, tablet count (30 tablets), and dispensing information. It is manufactured by Zydus Lifesciences Ltd. and distributed by Zydus Pharmaceuticals USA Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.